References
- 1. B. Vanhaesebroeck, L. Stephens and P. Hawkins, PI3K signalling: the path to discovery and understanding, Nat. Rev. Mol. Cell Biol.13 (2012) 195–203; https://doi.org/10.1038/nrm329010.1038/nrm329022358332
- 2. I. Vivanco and C. L. Sawyers, The phosphatidylinositol 3-kinase-AKT pathway in human cancer, Nat. Rev. Cancer2 (2002) 489–501; https://doi.org/10.1038/mrc839
- 3. B. Vanhaesebroeck and M. D. Waterfield, Signaling by distinct classes of phosphoinositide 3-kinases, Exp. Cell Res.253 (1999) 239–254; https://doi.org/10.1006/excr.1999.470110.1006/excr.1999.470110579926
- 4. L. C. Cantley, The phosphoinositide 3-kinase pathway, Science296 (2002) 1655–1657; https://doi.org/10.1126/science.296.5573.165510.1126/science.296.5573.165512040186
- 5. C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli and L. M. Amzel, The structure of a human p110 alpha/p85 alpha complex elucidates the effects of oncogenic PI3K alpha mutations, Science318 (2007) 1744–1748; https://doi.org/10.1126/science.115079910.1126/science.115079918079394
- 6. N. Miled, Y. Yan, W.-C. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H. J. Wolf-son, J. M. Backer and R. L. Williams, Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit, Science317 (2007) 239–242; https://doi.org/10.1126/science.113539410.1126/science.113539417626883
- 7. L. Zhao and P. K. Vogt, Helical domain and kinase domain mutations in p110 alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms, Proc. Natl. Acad. Sci. USA.105 (2008) 2652–2657; https://doi.org/10.1073/pnas.071216910510.1073/pnas.0712169105226819118268322
- 8. Y. Samuels and V. E. Velculescu, Oncogenic mutations of PIK3CA in human cancers, Cell Cycle3 (2004) 1221–1224; https://doi.org/10.4161/cc.3. https://doi.org/10.1164
- 9. Y. Samuels, L. A. Diaz, O. Schmidt-Kittler, J. M. Cummins, L. DeLong, I. Cheong, C. Rago, D. L. Huso, C. Lengauer, K. W. Kinzler, B. Vogelstein and V. E. Velculescu, Mutant PIK3CA promotes cell growth and invasion of human cancer cells, Cancer Cell7 (2005) 561–573; https://doi.org/10.1016/j.ccr.2005.05.014.10.1016/j.ccr.2005.05.01415950905
- 10. P. Liu, H. Cheng, S. Santiago, M. Raeder, F. Zhang, A. Isabella, J. Yang, D. J. Semaan, C. Chen, E. A. Fox, N. S. Gray, J. Monahan, R. Schlegel, R. Beroukhim, G. B. Mills and J. J. Zhao, Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms, Nat. Med.17 (2011) 1116–1120; https://doi.org/10.1038/nm.240210.1038/nm.2402316972421822287
- 11. L. Zhao and P. K. Vogt, Hot-spot mutations in p110α of phosphatidylinositol 3-kinase (PI3K): differential interactions with the regulatory subunit p85 and with RAS, Cell Cycle9 (2010) 596–600; https://doi.org/10.4161/cc.9.3.1059910.4161/cc.9.3.10599283581520009532
- 12. P. Liu, H. Cheng, T. M. Roberts and J. J. Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer, Nat. Rev. Drug Discov.8 (2009) 627–644; https://doi.org/10.1038/nrd292610.1038/nrd2926314256419644473
- 13. T. M. Bauer, M. R. Patel and J. R. Infante, Targeting PI3 kinase in cancer, Pharmacol. Ther.146 (2015) 53–60; https://doi.org/10.1016/j.pharmthera.2014.09.00610.1016/j.pharmthera.2014.09.00625240910
- 14. M. Cully, H. You, A. J. Levine and T. W. Mak, Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis, Nat. Rev. Cancer6 (2006) 184–192; https://doi.org/10.1038/nrc181910.1038/nrc181916453012
- 15. A. Carracedo and P. P. Pandolfi, The PTEN-PI3K pathway: of feedbacks and cross-talks, Oncogene27 (2008) 5527–5541; https://doi.org/10.1038/onc.2008.24710.1038/onc.2008.24718794886
- 16. M. Hayakawa, H. Kaizawa, H. Moritomo, T. Koizumi, T. Ohishi, M. Okada, M. Ohta, S.-I. Tsukamoto, P. Parker, P. Workman and M. Waterfield, Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110 alpha inhibitors, Bioorg. Med. Chem.14 (2006) 6847–6858; https://doi.org/10.1016/j.bmc.2006.06.04610.1016/j.bmc.2006.06.04616837202
- 17. M. Hayakawa, H. Kaizawa, K.-I. Kawaguchi, N. Ishikawa, T. Koizumi, T. Ohishi, M. Yamano, M. Okada, M. Ohta, S.-I. Tsukamoto, F. I. Raynaud, M. D. Waterfield, P. Parker and P. Workman, Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110 alpha inhibitors, Bioorg. Med. Chem.15 (2007) 403–412; https://doi.org/10.1016/j.bmc.2006.09.04710.1016/j.bmc.2006.09.04717049248
- 18. M. Hayakawa, H. Kaizawa, H. Moritomo, T. Koizumi, T. Ohishi, M. Yamano, M. Okada, M. Ohta, S. Tsukamoto, F. I. Raynaud, P. Workman, M. D. Waterfield and P. Parker, Synthesis and biological evaluation of pyrido[3’,2’:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors, Bioorg. Med. Chem. Lett.17 (2007) 2438–2442; https://doi.org/10.1016/j.bmcl.2007.02.03210.1016/j.bmcl.2007.02.03217339109
- 19. D. A. Sabbah, N. A. Simms, W. Wang, Y. Dong, E. L. Ezell, M. G. Brattain, J. L. Vennerstrom and H. A. Zhong, N-phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα), Bioorg. Med. Chem.20 (2012) 7175–7183; https://doi.org/10.1016/j.bmc.2012.09.05910.1016/j.bmc.2012.09.05923121722
- 20. D. A. Sabbah, B. Hishmah, K. Sweidan, S. Bardaweel, M. AlDamen, H. A. Zhong, R. Abu Khalaf, I. Hasan, T. Al-Qirim and G. Abu Sheikha, Structure-based design: Synthesis, X-ray crystallography, and biological evaluation of N-substituted-4-hydroxy-2-quinolone-3-carboxamides as potential cytotoxic agents, Anticancer Agents Med. Chem.18 (2018) 263–276; https://doi.org/10.2174/187152061766617091117115210.2174/187152061766617091117115228901259
- 21. D. A. Sabbah, F. Al-Tarawneh, W. H. Talib, K. Sweidan, S. K. Bardaweel, E. Al-Shalabi, H. A. Zhong, G. Abu Sheikha, R. Abu Khalaf and M. S. Mubarak, Benzoin Schiff bases: Design, synthesis, and biological evaluation as potential antitumor agents, Med. Chem.14 (2018) 695–708; https://doi.org/10.2174/157340641466618041216014210.2174/157340641466618041216014229651943
- 22. D. A. Sabbah, A. H. Ibrahim, W. H. Talib, K. M. Alqaisi, K. Sweidan, S. K. Bardaweel, G. A. Sheikha, H. A. Zhong, E. Al-Shalabi and R. A. Khalaf, Ligand-based drug design: Synthesis and biological evaluation of substituted benzoin derivatives as potential antitumor agents, Med. Chem.15 (2019) 417–429; https://doi.org/10.2174/157340641466618091211184610.2174/157340641466618091211184630207238
- 23. D. Kong and T. Yamori, Advances in development of phosphatidylinositol 3-kinase inhibitors, Curr. Top. Med. Chem.16 (2009) 2839–2854; https://doi.org/10.2174/09298670978880322210.2174/09298670978880322219689267
- 24. D. A. Sabbah, M. G. Brattain and H. A. Zhong, Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: Which way shall we go?, Curr. Med. Chem.18 (2011) 5528–5544; https://doi.org/10.2174/09298671179834729810.2174/09298671179834729822172063
- 25. D. A. Sabbah, J. Hu and H. A. Zhong, Advances in the development of class I phosphoinositide 3-kinase (PI3K), Curr. Top. Med. Chem.16 (2016) 1413–1426; https://doi.org/10.2174/156802661566615091511582310.2174/156802661566615091511582326369826
- 26. National Institutes of Health, National Cancer Institute, NCI Open Database Compounds, Release 4, NCI, Bethesda (MD) 2012; http://cactus.nci.nih.gov/download/nci, last access date June 15, 2017
- 27. D. A. Sabbah, N. A. Simms, M. G. Brattain, J. L. Vennerstrom and H. Zhong, Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases, Bioorg. Med. Chem. Lett.22 (2012) 876–880; https://doi.org/10.1016/j.bmcl.2011.12.04410.1016/j.bmcl.2011.12.044447244622212721
- 28. D. A. Sabbah, M. Saada, R. A. Khalaf, S. Bardaweel, K. Sweidan, T. Al-Qirim, A. Al-Zughier, H. A. Halim and G. A. Sheikha, Molecular modeling based approach, synthesis, and cytotoxic activity of novel benzoin derivatives targeting phosphoinostide 3-kinase (PI3Kα), Bioorg. Med. Chem. Lett.25 (2015) 3120–3124; http://dx.doi.org/https://doi.org/10.1016/j.bmcl.2015.06.01110.1016/j.bmcl.2015.06.01126099539
- 29. H. A. Younus, A. Hameed, A. Mahmood, M. S. Khan, M. Saeed, F. Batool, A. Asari, H. Mohamad, J. Pelletier, J. Sévigny, J. Iqbal and M. al-Rashida, Sulfonylhydrazones: Design, synthesis and investigation of ectonucleotidase (ALP & e5′NT) inhibition activities, Bioorg. Chem.100 (2020) Article ID 103827; https://doi.org/https://doi.org/10.1016/j.bioorg.2020.10382710.1016/j.bioorg.2020.10382732402802
- 30. W. H. Talib and A. M. Mahasneh, Antiproliferative activity of plant extracts used against cancer in traditional medicine, Sci. Pharm.78 (2010) 33–46; https://doi.org/10.3797/scipharm.0912-1110.3797/scipharm.0912-11300282621179373
- 31. W. H. Talib, Consumption of garlic and lemon aqueous extracts combination reduces tumor burden by angiogenesis inhibition, apoptosis induction, and immune system modulation, Nutr. J.43–44 (2017) 89–97; https://doi.org/https://doi.org/10.1016/j.nut.2017.06.01510.1016/j.nut.2017.06.01528935151
- 32. W. H. Talib, Regressions of breast carcinoma syngraft following treatment with piperine in combination with thymoquinone, Sci. Pharm.85 (2017) 27–38; https://doi.org/10.3390/scipharm8503002710.3390/scipharm85030027562051528671634
- 33. W. H. Talib and L. T. Al Kury, Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 – dependent apoptosis and inhibiting VEGF expression, Biomed. Pharmacother.107 (2018) 1488–1495; https://doi.org/10.1016/j.biopha.2018.08.13910.1016/j.biopha.2018.08.13930257366
- 34. D. A. Sabbah, J. L. Vennerstrom and H. Zhong, Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases, J. Chem. Inf. Model.50 (2010) 1887–1898; https://doi.org/https://doi.org/10.1021/ci100267910.1021/ci1002679448077220866085
- 35. D. Mandelker, S. B. Gabelli, O. Schmidt-Kittler, J. Zhu, I. Cheong, C.-H. Huang, K. W. Kinzler, B. Vogelstein and L. M. Amzel, A frequent kinase domain mutation that changes the interaction between PI3K alpha and the membrane, Proc. Natl. Acad. Sci. USA106 (2009) 16996–7001; https://doi.org/10.1073/pnas.090844410610.1073/pnas.0908444106276133419805105
- 36. Protein Preparation Wizard, Maestro, Macromodel, and QPLD-dock, Schrödinger, LLC, Portland, (OR), 2016
- 37. R. Hajjo, C. M. Grulke, A. Golbraikh, V. Setola, X.-P. Huang, B. L. Roth and A. Tropsha, Development, Validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs, J. Med. Chem.53 (2010) 7573–7586; https://doi.org/10.1021/jm100600y10.1021/jm100600y343829220958049
- 38. Alvascience, alvaDesc (software for molecular descriptors calculation) version 1.0.18, 2020, Lecco, Italy; https://www.alvascience.com
- 39. D. Szklarczyk, J. H. Morris, H. Cook, M. Kuhn, S. Wyder, M. Simonovic, A. Santos, N. T. Doncheva, A. Roth, P. Bork, L. J. Jensen and C. von Mering, The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible, Nucleic Acids Res.45 (2016) D362– D368; https://doi.org/10.1093/nar/gkw93710.1093/nar/gkw937521063727924014
- 40. M. Kanehisa, M. Araki, S. Goto, M. Hattori, M. Hirakawa, M. Itoh, T. Katayama, S. Kawashima, S. Okuda, T. Tokimatsu and Y. Yamanishi, KEGG for linking genomes to life and the environment, Nucleic Acids Res.36 (2007) D480–D484; https://doi.org/10.1093/nar/gkm88210.1093/nar/gkm882223887918077471
- 41. M. G. Brattain, A. E. Levine, S. Chakrabarty, L. C. Yeoman, J. K. V. Willson and B. Long, Heterogeneity of human colon carcinoma, Cancer Metastasis Rev.3 (1984) 177–191; https://doi.org/10.1007/bf0004838410.1007/BF000483846437669
- 42. J. Karar and A. Maity, PI3K/AKT/mTOR pathway in angiogenesis, Front. Mol. Neurosci.4 (2011) Article ID 51; https://doi.org/10.3389/fnmol.2011.0005110.3389/fnmol.2011.00051322899622144946
- 43. W. H. Talib, S. A. Al-Hadid, M. B. W. Ali, I. H. Al-Yasari and M. R. A. Ali, Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action, Breast Cancer (Dove Med Press)10 (2018) 207–217; https://doi.org/10.2147/bctt.s16781210.2147/BCTT.S167812627663730568488
- 44. R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis, P. S. Shenkin, Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem.47 (2004) 1739–1749; https://doi.org/10.1021/jm030643010.1021/jm030643015027865
- 45. R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin, D. T. Mainz, Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J. Med. Chem.49 (2006) 6177–6196; https://doi.org/10.1021/jm051256o10.1021/jm051256o17034125
- 46. K. Sweidan, D. A. Sabbah, S. Bardaweel, K. A. Dush, G. A. Sheikha, M. S. Mubarak, Computer-aided design, synthesis, and biological evaluation of new indole-2-carboxamide derivatives as PI3Kα/EGFR inhibitors, Bioorg. Med. Chem. Lett.26 (2016) 2685–2690; https://doi.org/10.1016/j.bmcl.2016.04.01110.1016/j.bmcl.2016.04.01127084677
- 47. Y. Zhao, X. Zhang, Y. Chen, S. Lu, Y. Peng, X. Wang, C. Guo, A. Zhou, J. Zhang, Y. Luo, Q. Shen, J. Ding, L. Meng and J. Zhang, Crystal structures of PI3Kα complexed with PI103 and its derivatives: new directions for inhibitors design, ACS Med. Chem. Lett.5 (2014) 138–142; https://doi.org/10.1021/ml400378e10.1021/ml400378e402762824900786
- 48. D. J. Adams and L. R. Morgan, Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development, Curr. Med. Chem.18 (2011) 1367–1372; https://doi.org/10.2174/09298671179502960910.2174/092986711795029609308683721366528
- 49. J. W. Godden, L. Xue and J. Bajorath, Combinatorial preferences affect molecular similarity/diversity calculations using binary fingerprints and Tanimoto coefficients, J. Chem. Inf. Comput. Sci.40 (2000) 163–166; https://doi.org/10.1021/ci990316u10.1021/ci990316u10661563
- 50. A. Kamal, S. Azeeza, E. V. Bharathi, M. S. Malik and R. V. Shetti, Search for new and novel chemotherapeutics for the treatment of human malignancies, Mini Rev. Med. Chem.10 (2010) 405–435; https://doi.org/10.2174/13895571079133091810.2174/13895571079133091820370699
- 51. A. Kamal, Y. V. V. Srikanth, M. Ashraf, M. N. A. Khan, T. B. Shaik, S. V. Kalivendi, N. Suri and A. K. Saxena, Synthesis and anticancer activities of new benzothiadiazinyl hydrazinecarboxamides and anilino[1,2,4]triazolo[1,5-b][1,2,4]thiadiazine 5,5-diones, Med. Chem.7 (2011) 165–172; https://doi.org/10.2174/15734061179556425910.2174/15734061179556425921486211
- 52. A. Martinez, C. Gil, A. Castro, A. M. Bruno, C. Pérez, C. Prieto and J. Otero, Benzothiadiazine dioxide human cytomegalovirus inhibitors: synthesis and antiviral evaluation of main hetero-cycle modified derivatives, Antivir. Chem. Chemother.14 (2003) 107–114; https://doi.org/10.1177/09563202030140020610.1177/09563202030140020612856922
- 53. E. Goffin, T. Drapier, A. P. Larsen, P. Geubelle, C. P. Ptak, S. Laulumaa, K. Rovinskaja, J. Gilissen, P. de Tullio, L. Olsen, K. Frydenvang, B. Pirotte, J. Hanson, R. E. Oswald, J. S. Kastrup and P. Fran-cotte, 7-Phenoxy-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with nanomolar potency, J. Med. Chem.61 (2018) 251–264; https://doi.org/10.1021/acs.jmedchem.7b0132310.1021/acs.jmedchem.7b01323605235629256599
- 54. The Molecular Operating, Environment Chemical Computing Group, Inc., Montreal (Quebec) Canada, 2016